On March 13, 2026, the Hong Kong stock market opened lower. The Hang Seng Index fell by 0.52%, the Hang Seng China Enterprises Index dropped by 0.33%, the Hang Seng Tech Index decreased by 0.42%, and the Hang Seng Composite Index declined by 0.20%.
OSL Group, MiniMax, CNOOC up over 1%; JD, Tencent open flat; Alibaba down slightly.
In terms of industry sectors, Hong Kong oil stocks showed positive performance. PETROCHINA rose by 1.22%, CNOOC increased by 1.37%, and CHINA SHENHUA gained 2.06%. However, Hong Kong aviation stocks and Hong Kong internet healthcare stocks experienced declines. CATHAY PAC AIR dropped by 3.00%, WUXI BIO fell by 0.57%, and YOFC decreased by 1.71%.
XIAOMI-W remained unchanged. Stellantis is reportedly in discussions with Chinese carmakers XPeng and Xiaomi to explore potential deals aimed at overhauling and strengthening its operations in Europe. These talks indicate Stellantis's strategic move to collaborate with Chinese companies to shore up its presence and competitiveness in the European automotive market.
XPENG-W remained unchanged. Stellantis is reportedly in discussions with Chinese carmakers XPeng and Xiaomi to explore potential deals aimed at overhauling and strengthening its operations in Europe. These talks indicate Stellantis's strategic move to collaborate with Chinese companies to shore up its presence and competitiveness in the European automotive market.
WUXI BIO fell by 0.57%. WuXi Biologics has signed a strategic cooperation agreement with Earendil Labs to provide integrated development and production services for multiple bispecific/multispecific antibodies and antibody-drug conjugates for the treatment of autoimmune diseases and tumors.
YOFC decreased by 1.71%. The Hong Kong stock market saw active trading in March 2026, with coal stocks like Yanzhou Coal Energy rising over 8%. YOFC's stock price initially rose but then fell, with UBS expressing concerns about its capacity expansion risks, leading to increased market risk aversion.
SINO BIOPHARM remained unchanged. Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, has achieved positive results in the Phase III clinical study of its innovative drug TQB3454 (IDH1 inhibitor) for the treatment of advanced biliary tract cancer with IDH1 mutation. The primary endpoints of progression-free survival and overall survival have reached the efficacy threshold, and the company plans to submit a marketing application soon.
CATHAY PAC AIR dropped by 3.00%. Cathay Pacific's revenue and profit for 2025 increased by about 10% year-on-year, with passenger load factor improving. The company plans to increase passenger capacity by 10% in 2026. Due to the Middle East situation, fuel costs have surged, leading to an adjustment in fuel surcharges. The fuel cost risk has not yet been fully reflected in the stock price.
Comments